Von Eschenbach Confirmation Clears Holds At Tail-End Of Lame Duck
This article was originally published in The Tan Sheet
Executive Summary
Andrew von Eschenbach's nomination to be FDA commissioner cleared the Senate by a comfortable 80-11 margin on Dec. 7, ending months of "holds" on the vote and opposition from both sides of the aisle
You may also be interested in...
Election 2008: Both Candidates Are Likely To Change FDA’s Direction
Whether Illinois Democrat Sen. Barack Obama or Arizona Republican Sen. John McCain wins the presidential election, signs point to a more activist FDA in 2009
Adverse Events Reporting System Needs Immediate Upgrade – FDA Consultant
FDA should resume an abandoned plan for software acquisition and "immediately" begin the process of upgrading Center for Drug Evaluation and Research's Adverse Events Reporting System, a consultant hired by the agency recommends in a report that is highly critical of the center's efforts to create a second-generation AERS
Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch
One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight